Topic: Health
Scientists at the University of Michigan have discovered a new way to treat prostate cancer that has become resistant to treatment. They found two pathways that can be targeted together to slow down tumor growth. This breakthrough could lead to new treatments for other types of cancer as well.
About one in eight men will be diagnosed with prostate cancer at some point in their lives. Prostate cancer is the second leading cause of cancer-related death among men in the United States. When prostate cancer spreads to other parts of the body, it becomes metastatic and can be very difficult to treat.
The researchers found that when prostate cancer cells become resistant to treatment, they change their identity by activating alternative biological pathways. This process is called transdifferentiation. The scientists identified two genes, TP53 and RB1, which are often lost in prostate cancer cells that have undergone this transformation.
To investigate further, the researchers examined several prostate cancer cell lines and studied which cellular pathways changed when TP53 and RB1 were missing. They found that there are two sides to this transition: loss of glandular genes and activation of cell programs that cause the identity to switch into stem cells.
The research team had previously shown that drugs known as BET bromodomain inhibitors can interfere with pathways that allow prostate cancer cells to activate alternative identity programs. However, those drugs alone did not permanently stop the cancer from progressing. In this new study, the researchers combined BET bromodomain inhibitors with another type of drug called DNA methyltransferase (DNMT) inhibitors.
The DNMT inhibitors can reactivate genes that have been switched off. The researchers were particularly interested in restoring glandular genes that are often lost as prostate cancer cells change identity. When they used both types of drugs together, they suppressed the growth of prostate cancer cell lines more effectively than either drug used by itself.
Why It Matters
This breakthrough could lead to new treatments for prostate cancer and potentially other types of cancer as well. It's a significant step forward in our understanding of how cancer cells change their identity and how we can target them more effectively.
Key Facts
- Prostate cancer is the second leading cause of cancer-related death among men in the United States.
- One in eight men will be diagnosed with prostate cancer at some point in their lives.
- The researchers identified two genes, TP53 and RB1, which are often lost in prostate cancer cells that have undergone transdifferentiation.
- BET bromodomain inhibitors can interfere with pathways that allow prostate cancer cells to activate alternative identity programs.
- Combining BET bromodomain inhibitors with DNMT inhibitors suppressed the growth of prostate cancer cell lines more effectively than either drug used by itself.
Key Terms
- Transdifferentiation
- A process where cancer cells change their identity and activate alternative biological pathways.
- BET bromodomain inhibitors
- Drugs that can interfere with pathways that allow prostate cancer cells to activate alternative identity programs.
- DNA methyltransferase (DNMT) inhibitors
- Drugs that can reactivate genes that have been switched off.
Implications
This breakthrough could lead to new treatments for prostate cancer and potentially other types of cancer as well. It's a significant step forward in our understanding of how cancer cells change their identity and how we can target them more effectively.
Leave a comment